Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» BeiGene
BeiGene
AbbVie sues rival BeiGene over alleged theft of cancer therapy secrets
Reuters
Tue, 09/10/24 - 09:15 am
AbbVie
BeiGene
trade secrets
legal
FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds
Fierce Pharma
Fri, 08/23/24 - 10:55 am
FDA
stomach cancer
Bristol Myers Squibb
Opdivo
Yervoy
Merck
Keytruda
BeiGene
Tevimbra
BeiGene debuts $800M biologics plant set to create ‘hundreds’ of jobs in New Jersey
Fierce Pharma
Tue, 07/23/24 - 06:33 pm
BeiGene
biologics
R&D
drug manufacturing
hirings
New Jersey
[podcast]Brukinsa approval raises BeiGene’s hematology profile
Medical Marketing and Media
Wed, 03/20/24 - 09:38 pm
BeiGene
Brukinsa
FDA
hematology
FDA approves expanded use of BeiGene's blood cancer drug
Reuters
Thu, 03/7/24 - 05:30 pm
BeiGene
FDA
Brukinsa
Gazyva
BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor
BioSpace
Tue, 11/21/23 - 11:54 am
BeiGene
Ensem
EXT-197
cancer
BeiGene to go solo with cancer drug after Novartis deal termination
Yahoo/Reuters
Tue, 09/19/23 - 10:30 am
BeiGene
Novartis
cancer
tislelizumab
Tivimbra
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban
Fierce Pharma
Thu, 08/3/23 - 11:22 am
Bristol Myers Squibb
BeiGene
Celgene
Novartis retreats from TIGIT, handing $300M candidate back to BeiGene
Fierce Biotech
Tue, 07/11/23 - 10:22 am
Novartis
anti-TIGIT
BeiGene
AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert
Fierce Pharma
Tue, 06/27/23 - 10:21 pm
AbbVie
patents
BeiGene
legal
Btk inhibitors
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
Fierce Pharma
Fri, 06/16/23 - 09:44 am
AbbVie
Pharmacyclics
BeiGene
Brukinsa
patents
Imbruvica
blood cancer
BeiGene's gastric cancer drug succeeds in late-stage trial
Reuters
Thu, 04/20/23 - 11:41 am
BeiGene
gastric cancer
clinical trials
tislelizumab
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint
NJ Business
Wed, 03/22/23 - 11:12 am
BeiGene
New Jersey
R&D
drug manufacturing
BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse
Fierce Biotech
Fri, 03/17/23 - 09:55 am
BeiGene
immuno-oncology
Leap Therapeutics
DKN-01
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Fierce Biotech
Sun, 03/5/23 - 03:06 pm
Big Pharma
Novo Nordisk
Moderna Therapeutics
Gilead Sciences
BeiGene
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
Fierce Pharma
Mon, 02/27/23 - 07:06 pm
BeiGene
Brukinsa
earnings
tislelizumab
This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more
RAPS.org
Sun, 01/22/23 - 01:00 pm
FDA
regulatory
clinical trials
clinicaltrials.gov
Eli Lilly
donanemab
Medtronic
BeiGene
Seagen
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
Endpoints
Thu, 01/19/23 - 08:55 pm
BeiGene
Brukinsa
CLL
FDA
Imbruvica
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
EP Vantage
Wed, 12/14/22 - 10:18 am
ASH 2022
Eli Lilly
BeiGene
Nurix Therapeutics
Brukinsa
pirtobrutinib
NX-2127
Pages
1
2
3
4
5
next ›
last »